Marc Dunoyer, chief financial officer at AstraZeneca Plc, is one of two new independent directors of Orchard Therapeutics Ltd, a developer of gene therapies for rare diseases. Mr Dunoyer previously worked at GlaxoSmithKline Plc where he helped establish the company’s rare disease unit. He holds a master of business administration degree from the Hautes Études Commerciales and a bachelor of law degree from Paris University, France.
Also joining the Orchard board is Charlie Rowland, recently chief executive of Aurinia Pharmaceuticals Inc, a clinical-stage company focusing on the global lupus nephritis market.
Orchard Therapeutics announced the appointments on 7 June 2018.
Copyright 2018 Evernow Publishing Ltd